Clinical Research Directory
Browse clinical research sites, groups, and studies.
AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Summary
Residual inflammatory risk remains a major contributor to adverse cardiovascular outcomes despite guideline-directed therapy. Although colchicine reduces cardiovascular events, its anti-inflammatory effects may extend beyond NLRP3 inhibition to involve AIM2 inflammasome suppression. The investigators hypothesized that dual NLRP3/AIM2 inhibition may provide an effective strategy for targeting residual inflammatory risk. Using molecular docking and a THP-1 cell-based dual-inflammasome model, the investigators screened approved drugs and identified leflunomide, eplerenone, and artesunate as candidate agents with greater IL-1β inhibitory activity than colchicine at clinically relevant concentrations. These findings highlight dual inflammasome inhibition as a potential therapeutic strategy for coronary heart disease.
Official title: The Effect of AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP in Patients After Coronary Intervention Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2026-11-11
Completion Date
2027-11-10
Last Updated
2026-11-20
Healthy Volunteers
No
Conditions
Interventions
Colchicine
Colchicine 0.5mg PO Qd
Eplerenone
Eplerenone 50mg PO Qd
Leflunomide
Leflunomide 10mg PO Qd
Artesunate
Artesunate 50mg PO Bid
Locations (1)
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China